Aktienanalyse zu Baxter International Inc. (BAX)BAXBaxter International Inc.

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. Its products are used in hospitals, rehabilitation centers, ambulatory surgery centers, and others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Baxter International Inc is currently priced at $25.30, which is below the average analyst price target of $27.75. The company has shown a year-to-date change of +29.74%, indicating strong performance. However, the forward P/E ratio is 11.57, which suggests it may not be undervalued. The main risk is the recent earnings guidance, which has been lowered by some analysts, reflecting uncertainty in future growth.